[{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucero Therapeutics Announces Promising Covid-19 Virus Laboratory Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pixatimod","moa":"Spike protein S1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zucero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zucero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zucero Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Pixatimod

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE 2024
                          Not Confirmed
                          FNCE 2024
                          Not Confirmed

                          Details : Zucero’s clinical-stage drug candidate pixatimod demonstrates potent antiviral activity against the COVID-19 virus in laboratory studies.

                          Brand Name : PG545

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 26, 2020

                          Lead Product(s) : Pixatimod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank